foxo4 dri senolytic peptide research FOXO4-DRI 10mg Frontiers | Senolytic Peptide FOXO4-DRI

| 2024 Edition GHK-Cu for research purposes generally comes as either an injectable peptide or in topical cream or serum form

Standard AOD-9604 Dosing Protocol Subcutaneous Injection Dosing: Beginner: 250 mcg per dose, once daily Intermediate: 300-400 mcg per dose, once daily or divided into two doses Advanced: 500 mcg per dose, once daily or 250 mcg twice daily Oral Administration Dosing (if using oral formulation): Standard: 1-2 mg per dose, once daily on empty stomach Higher protocols: Up to 5-10 mg daily, as studied in clinical trials Frequency: Once daily (morning preferred) or twice daily (morning and early afternoon) Timing: Best administered on an empty stomach, typically upon waking or before exercise Cycle Length: 12-16 weeks for initial assessment, with potential for longer protocols based on response Off Cycle: 4-8 weeks between cycles, though not strictly required based on current research Note: Start at the lower end of the dosing range to assess individual tolerance

Begin by thoroughly washing your hands and donning sterile protective clinical gloves and goggles

83702-10MG), both of which are MDR and MRP substrates

European Journal of Pharmacology